NM4TBProject reference: 18923
Funded under: FP6-LIFESCIHEALTH
New medicines for tuberculosis
Total cost:EUR 12 879 968
EU contribution:EUR 11 070 000
Call for proposal:FP6-2004-LIFESCIHEALTH-5
Funding scheme:IP - Integrated Project
The explicit aim of the NM4TB project is to successfully develop new drugs for the treatment of tuberculosis (TB) with the following desired properties: * High potency to reduce treatment duration, * Activity against persistent bacilli, * Inhibition of ne w target classes, * Activity against multidrug resistant TB, * Specificity for Mycobacterium tuberculosis. This will be achieved through an integrated approach implemented by a team that combines some of Europe's leading academic TB researchers with a maj or pharmaceutical company and three SMEs with a strong commitment to discovering new anti-infective agents. Four interlinked, cutting-edge work packages (WP1) have been assembled: * WP1 provides all of the enabling technologies expected of a modern drug development programme, * WP2 is devoted to validation of an attractive range of targets, * WP3 generates three dimensional structures of targets with their inhibitors, * WP4 provides an exhaustive approach to screening and lead optimization culminating in candidate drugs. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel, proprietary anti-TB agents in its drug development pipeline. Among the validated targets are several enzymes involved in highly druggable areas su ch as cell wall biogenesis, nucleic acid synthesis and central metabolic pathways for which assays amenable to high-throughput screening are available. Intensive efforts will focus on rapidly emerging targets that impact upon two as-yet untouched areas of the physiology of M. tuberculosis signal transduction pathways and persistence.